Research
Hormonal
Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.
If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.
ModerateRefutesLOW confidence
No significant association was demonstrated for PJI following total knee arthroplasty or for revision procedures.
Why this rating
Low certainty for TKA-PJI and revision outcomes due to heterogeneity and observational design.
Source
Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
André Daniel Aires Fernandes et al. · Cureus · 2025
DOI 10.7759/cureus.99805
Meta-analysis · 8 studies
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →